Evidence map›Paper›PMID 42587147›Full record

ArticleNature2026

Rb-driven transcription limits its tumour-suppressive effects in breast cancer.

April C Watt, Antonio Ahn, Catherine Blyth, Julia R Dixon-Douglas, Krutika Ambani, Rhiannon Coulson, Michael Taylor, Keefe T Chan, Catherine Dietrich, Brendan E Russ and 14 more

Abstract read
In one paragraph

Article in Nature, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

24 authors.

April C Watt *Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia.ORCID http://orcid.org/0000-0002-5145-5334
Antonio Ahn *Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia.
Catherine BlythPeter MacCallum Cancer Centre, Melbourne, Victoria, Australia.ORCID http://orcid.org/0000-0002-6653-1723
Julia R Dixon-DouglasPeter MacCallum Cancer Centre, Melbourne, Victoria, Australia.
Krutika AmbaniPeter MacCallum Cancer Centre, Melbourne, Victoria, Australia.
Rhiannon CoulsonPeter MacCallum Cancer Centre, Melbourne, Victoria, Australia.
Michael TaylorPeter MacCallum Cancer Centre, Melbourne, Victoria, Australia.ORCID http://orcid.org/0000-0003-1115-5449
Keefe T ChanPeter MacCallum Cancer Centre, Melbourne, Victoria, Australia.ORCID http://orcid.org/0000-0001-6114-3724
Catherine DietrichPeter MacCallum Cancer Centre, Melbourne, Victoria, Australia.
Brendan E RussPeter MacCallum Cancer Centre, Melbourne, Victoria, Australia.ORCID http://orcid.org/0000-0001-6862-5283
Susanne RammPeter MacCallum Cancer Centre, Melbourne, Victoria, Australia.
Christabella A MahendraPeter MacCallum Cancer Centre, Melbourne, Victoria, Australia.
Kun-Hui LuPeter MacCallum Cancer Centre, Melbourne, Victoria, Australia.
Nichelle PiresPeter MacCallum Cancer Centre, Melbourne, Victoria, Australia.ORCID http://orcid.org/0000-0002-0485-2927
Jesus Garcia-SannicolasPeter MacCallum Cancer Centre, Melbourne, Victoria, Australia.ORCID http://orcid.org/0009-0007-2344-1246
Olivia VoulgarisPeter MacCallum Cancer Centre, Melbourne, Victoria, Australia.ORCID http://orcid.org/0009-0008-1168-8521
Sheena NunagGarvan Institute of Medical Research, Sydney, New South Wales, Australia.
Ching-Seng AngBio21 Mass Spectrometry and Proteomics Facility, University of Melbourne, Parkville, Victoria, Australia.
Mark A DawsonPeter MacCallum Cancer Centre, Melbourne, Victoria, Australia.ORCID http://orcid.org/0000-0002-5464-5029
Elgene LimGarvan Institute of Medical Research, Sydney, New South Wales, Australia.ORCID http://orcid.org/0000-0001-8065-8838
Monica ArnedosDepartment of Medicine, Institut Bergonie, Bordeaux, France.
Sarat ChandarlapatyHuman Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA.ORCID http://orcid.org/0000-0003-4532-8053
Fabrice AndréINSERM U981, Molecular Predictors and Novel Targets in Oncology, Gustave Roussy, Villejuif, France.ORCID http://orcid.org/0000-0001-5795-8357
Shom GoelPeter MacCallum Cancer Centre, Melbourne, Victoria, Australia. shom.goel@petermac.org.ORCID http://orcid.org/0000-0001-8329-9084

Funding

X-RAY CRYSTALLOGRAPHYP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI SELWYN M VICKERS · 1985 to 2026
$347.4M
NCI NIH HHS P30 CA008748
6 · The paper itself

Abstract

The retinoblastoma protein (Rb) is a tumour suppressor best known for repressing E2F transcription factors and halting cell cycle progression

Indexed as

Breast NeoplasmsGene Expression Regulation, NeoplasticGenes, Tumor SuppressorRetinoblastoma ProteinTranscription, GeneticAnimalsCell Line, TumorCell ProliferationCyclin-Dependent Kinase 4Cyclin-Dependent Kinase 6Enhancer Elements, GeneticFemaleHumansMicePhosphorylationPromoter Regions, GeneticCDK4 protein, humanCyclin-Dependent Kinase 4Cyclin-Dependent Kinase 6Receptors, EstrogenRetinoblastoma Protein

Identifiers

PMID42587147
PMCPMC13558077

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.